- Home
- BFRI vs CYCN Comparison
BFRI vs CYCN Comparison
Compare BFRI & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRI
- CYCN
- Stock Information
- Founded
- BFRI 1997
- CYCN 2018
- Country
- BFRI United States
- CYCN United States
- Employees
- BFRI N/A
- CYCN N/A
- Industry
- BFRI Biotechnology: Pharmaceutical Preparations
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- BFRI Health Care
- CYCN Health Care
- Exchange
- BFRI Nasdaq
- CYCN Nasdaq
- Market Cap
- BFRI 7.5M
- CYCN 6.5M
- IPO Year
- BFRI 2021
- CYCN N/A
- Fundamental
- Price
- BFRI $0.70
- CYCN $3.36
- Analyst Decision
- BFRI Strong Buy
- CYCN
- Analyst Count
- BFRI 1
- CYCN 0
- Target Price
- BFRI $2.75
- CYCN N/A
- AVG Volume (30 Days)
- BFRI 175.2K
- CYCN 25.7K
- Earning Date
- BFRI 08-13-2025
- CYCN 08-06-2025
- Dividend Yield
- BFRI N/A
- CYCN N/A
- EPS Growth
- BFRI N/A
- CYCN N/A
- EPS
- BFRI N/A
- CYCN N/A
- Revenue
- BFRI $37,997,000.00
- CYCN $2,081,000.00
- Revenue This Year
- BFRI $11.75
- CYCN N/A
- Revenue Next Year
- BFRI $17.09
- CYCN N/A
- P/E Ratio
- BFRI N/A
- CYCN N/A
- Revenue Growth
- BFRI 14.28
- CYCN N/A
- 52 Week Low
- BFRI $0.54
- CYCN $1.27
- 52 Week High
- BFRI $2.22
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- BFRI 57.11
- CYCN 60.16
- Support Level
- BFRI $0.59
- CYCN $3.02
- Resistance Level
- BFRI $0.73
- CYCN $3.50
- Average True Range (ATR)
- BFRI 0.05
- CYCN 0.26
- MACD
- BFRI 0.01
- CYCN 0.03
- Stochastic Oscillator
- BFRI 66.46
- CYCN 82.28
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.